Navigation Links
YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA
Date:1/26/2010

cation">Singapore and India as well as the United States. Enrollment is targeted for completion toward the end of 2010.

About YM BioSciences

YM BioSciences Inc. is a life sciences product development. Together with the products from merging the Australian company, Cytopia Ltd, into YM, which is to occur January 28, 2010, the Company is currently developing four late-stage products: nimotuzumab, an EGFR-targeting Affinity-Optimized Antibody(TM); CYT 3878 JAK 1/2 small molecule, CYT 997, a potent, vascular disrupting agent and AeroLEF(R), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.

Nimotuzumab is a humanized monoclonal antibody in development worldwide, targeting multiple tumor types primarily in combination with radiation and chemoradiation. It is importantly differentiated from all other currently marketed EGFR-targeting agents due to its remarkably benign side-effect profile. Nimotuzumab's anti-tumor activity has led to its approval for marketing in 23 countries. In more than 9,000 patients reported as having been treated with nimotuzumab worldwide to date, Grade IV incidents of radiation dermatitis and incidents of severe rash have been only rarely observed and reports of the other severe side-effects that are typical of EGFR-targeting molecules have been equally rare. Nimotuzumab is licensed to YM's majority-owned, Canadian subsidiary, CIMYM BioSciences Inc., by CIMAB S.A., and was developed at the Center of Molecular Immunology. The products being developed by Cytopia, the JAK 1/2 and the VDA molecule that derived from the JAK molecule, resulted from the discovery by Dr '/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... October 25, 2014 Berkshire Corporation, ... pleased to announce the release of the ValuSeal® ... level of contamination containment in critical processing applications. ... and higher cleanroom environments, ValuSeal® IonX™ is a ... laundered wiper that continues Berkshire’s innovative focus on ...
(Date:10/25/2014)...  RegeneRx Biopharmaceuticals, Inc. (OTCBB: RGRX) ("the Company" or ... International Symposium on Thymosins in Health and Disease in ... "When thymosin beta 4 (TB4) linked with rhodamine (a ... in a rodent model of stroke, it was visualized ... (the functional tissue of the brain).   The leakage of ...
(Date:10/25/2014)... DUBLIN , October 24, 2014 /PRNewswire/ ... and Markets ( http://www.researchandmarkets.com/research/t5t5pd/the_global_market ) has announced the ... Carbon Nanotubes, Graphene And Other 2-D Nanomaterials ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,CNTs and graphene ... fibres known to man, with a performance-per-weight ...
(Date:10/22/2014)... , Oct. 22, 2014  Actavis plc (NYSE: ... company, and Rhythm, a biopharmaceutical company, today announced that ... Rhythm,s wholly owned subsidiary, Rhythm Health, Inc., which is ... treatment of diabetic gastroparesis and other GI functional disorders. ... 2 trial of relamorelin for the treatment of diabetic ...
Breaking Biology Technology:Ions Are Bygones, Berkshire Announces the Release of New Innovative Cleanroom Wipers 2Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 2The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 2The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 3The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5
... Mich., April 25 The Fraunhofer Center ... the BU,Center for Nanoscience and Nanobiotechnology hosted ... for a tour of their world class,facilities ... The intensive tour included demonstrations of ...
... April 25 /Xinhua-PRNewswire-FirstCall/ -- China Yingxia,International, Inc. ... "the,Company"), a leading provider in the nutraceutical ... of organic nutritional food,products, supplements, and personal ... ("PRC"), today announced that it has formally ...
... BASINGSTOKE, England and PHILADELPHIA, April 25 /PRNewswire-FirstCall/,-- Shire plc (LSE: ... the three months to March,31, 2008., Q1 2008 ... - New product sales(1) $216m, 34% of product sales ... - US GAAP Operating income up 15% to $163m ...
Cached Biology Technology:Fraunhofer and Boston University Hosted Prestigious SME Tour 2China Yingxia International, Inc. Acquires Grocery Chain and Online Distribution Network 2China Yingxia International, Inc. Acquires Grocery Chain and Online Distribution Network 3Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance 2Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance 3Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance 4Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance 5Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance 6Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance 7Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance 8Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance 9Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance 10Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance 11Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance 12Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance 13Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance 14Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance 15Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance 16Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance 17Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance 18Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance 19Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance 20Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance 21Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance 22Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance 23Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance 24Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance 25Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance 26Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance 27Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance 28Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance 29Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance 30Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance 31Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance 32Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance 33
(Date:10/17/2014)... knowledge regarding Ebola is critical and pertinent for practicing ... global outbreak and epidemic. The Journal, Disaster Medicine ... issue, Ebola Virus and Public Health, to surround the ... this critical societal moment. , On October 17, ... Clinicians . The primer was prepared by Dr. Eric ...
(Date:10/17/2014)... German . ... When treating overdoses, doctors are often limited to supportive therapy ... is a combination of drugs involved. So what can be ... grandmother,s pills? ETH professor Jean-Christophe Leroux from the Institute of ... to this question. "The task was to develop an agent ...
(Date:10/16/2014)... synthesis of recent research findings to inform their management ... states. , The Ecology and Management of Moist ... of the Relevant Biophysical Science and Implications for Future ... U.S. Forest Service,s Pacific Northwest Research Station, is a ... synthesis of the large body of scientific information on ...
Breaking Biology News(10 mins):Emergency aid for overdoses 2Emergency aid for overdoses 3New report synthesizes best available science on management of moist mixed-conifer forests 2
... Polycyclic Aromatic Compounds (PACs) on terrestrial and benthic invertebrates ... sediment contamination. Effects are assessed exposing the organisms to ... cases this results in highly predictable effects on development ... that the effects of prolonged exposure can be very ...
... researchers under the leadership of Vici-winner Merel Kindt has ... in human volunteers by administering the beta-blocker propranolol. Interestingly, ... of time. Top journal Nature Neuroscience published ... recently, it was assumed that the fear memory could ...
... well crickets adapt to rising temperatures may provide clues ... UCF scientist Wade Winterhalter landed an $860,000 grant ... study that fuses global warming models with a biological ... ground cricket, also known as the Allonemobius socius. ...
Cached Biology News:Soil and sediment contamination assessment more accurate 2An end to fear 2Crickets may predict human survivability during global warming 2
HybriWell™ hybridization sealing system, 20 mm diameter chamber, 0.15 mm deep *set of 100*...
Recombinant Feline IL-5...
... Checker Kits provide two highly efficient methods ... time-consuming plasmid preparation. By using the large-scale ... need to do is to transfer partial ... the transformation plates into the solutions provided ...
Recombinant Equine IL-4, CF...
Biology Products: